Alimta

... /* GENERAL FONT AND LINK SETTINGS */ BODY, PRE, TR, TD, TH, P {font-family: Arial, Helvetica, sans-serif; font-size: small; color: #000000; font-weight: normal; font-style: normal} P {margin-top: 0px; margin-bottom: 1em} TH {font-weight: bold} .epi-fontSm, .wsui-font-small {font-size: x-small} .epi-font, .wsui-font {font-size: small} .epi-fontLg, .wsui-font-large {font-size: medium} a:link {color: #000066; text-decoration: underline} a:visited {color: #000066; text-decoration: underline} a:active, a:hover {color: #660000; text-decoration: underline} a.epi-headline {font-weight: normal; text-decoration: underline !

important} /* FOR TRAIL, PAGE, AND SECTION TITLES */ /* NAVIGATION TRAILS */ .epi-trail, .wsui-trail {font-family: Arial, Helvetica, sans-serif; font-size: small; color: #666666; font-weight: normal; margin-bottom: 0px} .epi-trail a, .wsui-trail a {color: #666666 !

important; text-decoration: none !

important} .epi-trail a:hover, .wsui-trail a:hover {color: #666666; text-decoration: underline !

important} .epi-trailOn, .wsui-trail-current {font-family: Arial, Helvetica, sans-serif; font-size: small; color: #000000; font-weight: bold; margin-bottom: 0px} /* PAGE TITLES */ h1, .epi-pageTitle, .wsui-page-title {font-family: Arial, Helvetica, sans-serif; font-size: medium; color: #663300; font-weight: bold; margin-bottom: 0px} /* SECTION TITLES*/ h2, .epi-sectionTitle, .wsui-section-title {font-family: Arial, Helvetica, sans-serif; font...

... Tomudex® Plus Eloxatin® Effective in Gemzar®-Resistant Metastatic Pancreatic Cancer Select a state - Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming Patient Home Professional Home Cancer Consultants Home Search: Professional Site • CME • Conference Coverage • Professional News • Drug Pipeline • Medline Main Menu Home Conference Coverage Professional Education Cancer News Disease Centers Physician Resources About Us Quick Links Information by Disease All Acute Leukemia Bladder Cancer Bone Cancer Brain Cancer Breast Cancer Cervical Cancer Chronic Leukemia Colon Cancer Gastric Cancer Head and Neck Cancers Liver Lung Cancer Lymphoma Myelodysplastic Syndrome Melanoma Mesothelioma Multiple Myeloma NSCLC Ovarian Cancer Pancreatic Cancer Prostate Cancer Rectal Cancer Renal Cancer SCLC Cancer News Select Cancer Type Anal Cancer Anemia Bladder Cancer Brain and CNS Cancers Breast Cancer CAM Carcinoid Tumors Cervical Cancer CINV Colon Cancer Esophageal Cancer Gastric Cancer General Head and Neck Cancers HIV Cancers Hodgkin's L...

... Stock Market News and Investment Information RSS (Adds analyst, updates shares) PARIS, March 24 (Reuters) - Sanofi-Aventis (SASY.PA: Quote, Profile, Research) has won backing for the use of its Taxotere treatment in advanced stomach cancer from a European Union health panel, the world's third largest drugmaker said on Friday.

Taxotere was Sanofi's third best-selling drug last year, after blood thinners Plavix and Lovenox, with 1.609 billion euros ($1.93 billion) in sales and its wider use could secure sales growth amid rivalry from generic and branded cancer drugs.

The European Medicines Agency's Committee for Medicinal Products for Human Use gave a positive opinion on Taxotere - already used to fight several other cancers - in the new line of treatment.

It still needs the European Commission's ma...